Giant Biotech (02367.HK): Recombinant Collagen Leader Combines Production and Research to Set an Industry Benchmark
Angel of the Times (06699.HK): Domestic invisible orthodontic leader accelerates breakthrough in overseas markets
CMB International: Maintaining Giant Biotech's (02367) “Buy” Rating Target Price Raised to HK$60.83
Angel of the Times (06699.HK): Achieving rapid growth in the number of cases, rapid progress in international business
Angel of the Times (6699.HK): The number of overseas cases exceeded expectations in '23, profits were slightly lower than expected due to increased investment in international business
Giant Biotech (2367.HK) tracking review: Online channels continue to boost makeup device collaboration to help growth
Haohai Biotechnology (06826.HK): The Q1 profit side slightly exceeded expectations and the profitability was significantly optimized
Giant Biotech (02367.HK): Kefumei's large single product volume continues to focus on medical and aesthetic products approved for catalysis
Giant Life (02367.HK): Good Wind takes the lead in recombinant collagen to Qingyun
Giant Biotech (2367.HK) Investment Value Analysis Report: The recombinant collagen market is expected to grow rapidly, and the company's star products achieve word-of-mouth and sales growth
Sansheng Pharmaceutical (01530.HK): Approval of ITP indications for children in Terbi Australia is expected to support continued income growth
Giusi Biotech (02367.HK) Annual Report Review Report: The company's performance achieved impressive growth and steadily promoted the collaborative development of cosmetic equipment
Giant Biotech (2367.HK) 2023 Report Review: Expanding Multiple Categories and Multiple Scenes to Accelerate Online Penetration
Research Report: Zheshang Securities: Maintaining Fosun Pharmaceuticals' “Buy” Rating, Optimistic About the Company's International Implementation
Zhongtai Securities released a research report on April 8 stating that it gave Fosun Pharmaceuticals (600196.SH) a purchase rating. The main reasons for the rating include: 1) the pharmaceutical industry remains steady, and investment in innovation remain
Beautiful Garden Healthcare (02373.HK): Performance is in line with expectations and the acquisition of Nariel Strong Alliance
Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)
Kangzhe Pharmaceutical (00867.HK): Performance is lower than expected, and new products are expected to accelerate contributions
Giusi Biotech (2367.HK) 2023 Annual Report Review: Performance Exceeds Expectations, Skin Revitalization Products are progressing smoothly
Giant Biotech (02367.HK): The core single product, a high-speed growth injection product, is about to be launched